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Abstract
Background: Celiac disease (CD) is an autoimmune chronic enteropathy of the small intestine caused by exposure
to gluten in genetically predisposed individuals. CD is not easy to diagnose due to its unspecific symptomatology,
especially in adults, a diagnosed/undiagnosed ratio of 1:7 is estimated. CD does not have its own code in the
International Classification of Primary Care (ICPC) but it is coded under code D99 “Disease digestive system, other”,
which hinders diagnosis, intervention and research. The aim of this study is to investigate the prevalence of CD in
Aragón, Spain, using the information available from Primary Care, as well as to discuss the difficulties involved in
determining prevalence of CD from data collected at this level of medical intervention.
Methods: We designed an epidemiological cross-sectional study and analysed 26,964 electronic clinical records
from the Aragonese Health Service under code ICPC D99 collected up to December 31st, 2016. The clinical records
were classified by their editable field “descriptor” according to their probability of being related to CD. Analyses of
gender, age, age at diagnosis, province and health sector were carried out.
Results: We found 4534 clinical records under 293 different descriptors with a high probability of referring to CD.
Prevalence in Aragón was estimated to be 0.35% ranging from 0.24 to 0.81% with important differences among
health sectors.
Conclusions: The prevalence of 0.35% is a long way from the generally accepted 1% but within the usually
considered ratio 1:7 of diagnosed:undiagnosed cases. Differences among sectors should be carefully analysed.
Lacking its own ICPC code, diagnosis of CD in Primary Care Services is not included in a single category, but it is
distributed under several descriptors, which makes it difficult to offer any firm diagnosis for treatment and hinders
research. Finally, the high prevalence of CD justifies its own ICPC code and the need to withdraw CD from the
generic D99 code “Disease digestive system other”.
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Background
According to the Oslo definitions [1], celiac disease is a
chronic small intestinal immune-mediated enteropathy
triggered by exposure to dietary gluten in genetically pre-
disposed people. This gluten is present in cereals such as
wheat, barley, rye and, probably, in some types of oats [2].
This causes serious enteropathy of the small intestinal
mucosa, which hinders correct nutrient uptake.
According to the European Society for Paediatric Gastro-
enterology Hepatology and Nutrition (ESPGHAN), the
diagnosis of CD relies on gluten-dependent symptoms,
CD-specific antibody levels, the presence of HLA-DQ2
and/or HLA-DQ8, and characteristic histological changes
in the duodenal biopsy [3]. Currently, the only known treat-
ment for CD is to follow a strict gluten-free diet for life.
CD is one of the most common chronic intestinal dis-
eases [4]. Since CD is genetically mediated [1, 3], its
prevalence depends on the frequency distribution of the
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HLA-DQ2 and HLA-DQ8 haplotypes among population
[5]. Depending on the country, this distribution of HLA-
DQ2 and DQ-8 reaches up to 40% [6] but the trigger
factors for CD still remain unknown [7]. Previous studies
report a prevalence for CD of 0.71% [8] in the USA and
0.1–2.8% in Europe [9], while a 1% prevalence is widely
accepted [10]. Unfortunately there are few studies on
prevalence of CD in Spain [11–15] and furthermore, dif-
ferences among them are considerable, ranging from 0.3
to 1.4% [3]. No environmental or lifestyle factors that
may explain these differences have been identified. Stud-
ies on prevalence indicate a 2.8:1 female/male ratio [16].
Some research suggests that this gender difference may
be due to a later diagnosis in males [17] or to the fact
that the non-classical forms of the disease may remain
undiagnosed in men [18].
In recent decades, prevalence studies have shown that
CD is a worldwide, frequent disease, which affects both
children and adults [7, 10]. It is difficult to diagnose on
account of the variety of symptoms it presents [1]. Only
a small part of people affected by CD would show the
classic, evident signs of the disease, while the majority
would have the asymptomatic form. Thus, the variety of
clinical symptoms of this illness hinders its diagnosis
and would explain an underdiagnosis of 1:3 to 1:9 of
diagnosed/undiagnosed cases [3, 18–20].
Traditionally, professionals have used different
terms to refer to CD. Terms such as sprue, coeliac
sprue, non-tropical sprue, idiopathic steatorrhea, glu-
ten-sensitive enteropathy and gluten intolerance have
been used as equivalents, but nowadays, their use is
discouraged by the Oslo Group [1]. This group dis-
courages the use of gluten intolerance and gluten sen-
sitivity, which should be replaced by celiac disease or
by non-celiac gluten sensitivity, respectively. Gluten
sensitivity, therefore, would refer to those individuals
with clinical manifestations triggered by gluten intake
when CD has been excluded.
The International Classification of Primary Care is a
classification method for Primary Care Services. It
contributes to labelling the patient’s reason for en-
counter (RFE), to managing diagnosis, to designing
primary health care interventions and to order data
for research. It was developed by the WONCA Inter-
national Classification Committee (WICC) and was
first published in 1987. A revision with new criteria
and definitions was published in 1998. It was ac-
cepted by the World Health Organization’s (WHO)
Family of International Classifications. This classifica-
tion was developed in response to the need of quality
information on Primary Care.
From the early 2000s, the Aragonese Health Care Ser-
vice launched the implementation of electronic clinical
records in all its Primary Care centres, a process which
was completed in 2011. Those records are coded accord-
ing to this international classification.
The International Classification of Primary Care con-
tains 17 chapters with Chapter D being for Digestive
Diseases". Within this chapter, CD is coded under D99
“Disease digestive system other”, as there is no specific
label for CD.
The autonomous community of Aragon is located in
northeastern Spain. It is composed of three provinces,
from north to south: Huesca, Zaragoza, and Teruel. It
is divided into 8 health sectors with their own second-
ary health services and 127 health areas. Aragon has 1.3
million inhabitants. It comprises 33 counties.
Previous research based on data of 2011 estimated the
prevalence of CD in Aragon at 0.15% (0.36% in Huesca,
0.12% in Zaragoza and 0.07% in Teruel) [21]. The
increase of social awareness and the better knowledge of
CD in recent years lead us to hypothesize a significant
growth of the prevalence of CD in 2016 compared
with 2011.
Therefore, the objectives of this investigation were: i)
to study the quality of the information regarding CD in
Primary Care available to General Practitioners. ii) to
study the prevalence of CD in the community from the
information in Primary Care.
Methods
Participants
The study population comprised patients in the Ara-
gonese Health Services with code D99 (“Disease di-
gestive system, other”) in the ICPC up to December
31, 2016. Data were requested from the Department
of Health, with the following anonymized variables:
patient code, gender, date of birth, descriptor, date of
diagnosis, doctor’s code, area of residence, centre, zip
code and nationality. These data were produced in
the daily practice of general practitioners in their Pri-
mary Care centre.
Classification process
26,965 clinical records of patients with an age range of 1 to
107 years old from 842 municipalities in Aragon were
analysed.
Since all clinical records belonged to D99 “Disease di-
gestive system, other”, records were classified using the
database field named “descriptor”, in which family doc-
tors can introduce their clinical impression.
The research team classified the cases into three
groups on the basis of their descriptors and according
to the patient’s likelihood of a suffering from CD:
“strong evidence group” (with a descriptor making spe-
cific mention to a firm CD diagnosis or gluten in-
tolerance); “weak evidence group” (with references to
gluten or CD, but no firm diagnosis); and the rest of
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the clinical records were assigned to the “no evidence
group”.
Statistical analysis
Distribution by province, gender, age, date of diagnosis,
age at diagnosis, medical centre, doctor and nationality
was analysed. In order to compare the prevalence of CD
in different periods, a two-sample test of proportions
was carried out. Previously, data were standardised for
gender and age and 0.05 was taken as being statistically
significant throughout.
SPSS v.25 programme was used for descriptive statis-
tical analysis and this study was approved by the Ethics
Committee of Research of Aragon (CEICA), registered
under number PI 14/0011.
Results
The analysis of the 26,965 records showed 4534 (16,
81%) strong evidence CD cases distributed in 293 differ-
ent descriptors. There were other 1198 (4,44%) patients
with weak evidence of suffering from the disease,
distributed under 729 additional descriptors. The 134
cases under the descriptor “malabsorption syndrome”
were assigned to this weak evidence group because their
etiology may be different to CD. 8 cases described as
“gluten sensitive” were expressly assigned to this second
group. Finally, 21,233 were classified into the no evi-
dence group (Table 1).
In the strong evidence group, only 3637 (80,2%) were
under the unmistakable categories of NC celiac disease,
celiac disease and Celiac, Disease, while the remaining
897 came under headings, such as “gluten enteropathy”,
“gluten enteropat. by” or other categories edited by fam-
ily doctors and classified into the strong evidence group
by this research team (Table 2).
Of the 4534 CD cases identified (71.8% female), the youn-
gest patient was 2 years old and the oldest 102 (M: 38.97;
SD: 20.85) (Table 3).
Mean age at diagnosis was 32.42 years, with a standard
deviation of 21.05, but with a range of just a few months
to 98 years (Fig. 1).
The mode for year of diagnosis was 2016 with 571
cases. A significant increase in diagnoses is observed
from 2000, reaching more than 500 cases per year in the
last three years of the study (Fig. 2).
Prevalence
Prevalence of CD was estimated in 0.35% in Aragon.
Prevalence by province was 0.81% in Huesca, 0.25% in
Zaragoza and 0.24% in Teruel. Regarding their national-
ity, 4362 (96.2%) were Spanish citizens and the rest were
from 20 other different nationalities.
The analysis by health sectors is shown in Table 4.
Only sector 4 approaches the expected prevalence of 1%,
while most of the sectors are within the usual diag-
nosed/undiagnosed ratio of 1:7.
Table 1 Group classification by probability of suffering from CD
Group n
D99 code 26,965
Strong evidence group 4534 in 293 descriptors
“NC celiac disease”, “celiac
disease” and “Celiac. Disease”
3637 (80.22%)
“Gluten enteropathy”, “gluten
enteropat. by” and others
897
Weak evidence group 1198 in 729 descriptors
No evidence group 21,233
Table 2 Examples of descriptors for the strong evidence group. Boldfaced terms are discouraged by Oslo Group
Rank Descriptor n Percentage Cumulative percentage
1. Celiac Disease NC 1,972 43.5 43.5
2. Celiac, Disease 1,539 33.9 77.4
3. Enteropathy by gluten 368 8.1 85.6
4. Gluten enteropat. by 141 3.1 88.7
5. Coeliac Disease 126 2.8 91.4
6. Intolerance to gluten 27 0.6 92
7. Celiac 17 0.4 92.4
8. Gluten Intolerance 15 0.3 92.7
9. Adult Celiac Disease 6 0.1 92.9
10. Coeliac 5 0.1 93
11. Intolerance to gluten and lactose 5 0.1 93.1
12. Others 313 6.9 100
Note: Authors have decided to literally translate the terms into English, as they appear to GPs in the clinical records, to show the abuse of slightly different terms
when referring to Celiac Disease
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When we analyse the prevalence by age group, we see
that it is similar for children and adolescents. However, as
age increases, important differences appear among ratios,
being Teruel the province with lower figures. Prevalence
in Huesca shows an atypical evolution through age, with
better figures between 30 and 59 years old (Table 5).
An analysis by counties reveals important differences
among them (Fig. 3).
Our study shows that the number of detected cases
has duplicated in Aragon since 2011, in comparison with
those found in the previous research [21] (Table 6).
If we standardise the prevalence for gender and age
(Table 7), and we compare both periods, all values
are significant (p < 0.05) and therefore, we can
conclude that prevalence of CD is greater in 2016
than in 2011, both in the whole of Aragon and in
each province.
Discussion
Prevalence
This study shows that the number of detected cases has
duplicated in Aragon since 2011 [21]. Although these
results are promising, they are far from the generally
accepted figure of 1% [9, 22]. Several factors may
account for these results such as: a) the improvement
of methods of diagnosis, b) stronger awareness among
general practitioners when searching for CD in children
and adults, c) greater patient awareness towards unspe-
cific symptomatology, which will make them persevere
to obtain a firm diagnosis.
According to our research, prevalence in Aragon
stands at 0.35%. It should be noted that this remains
far from the general accepted prevalence, but it falls
within the underdiagnosis of 1:5–7 [16], showing a
good detection capacity from the National Health Ser-
vice, at least similar to nearby countries. The preva-
lence found in Huesca is three times higher than in
Zaragoza and five times higher than in Teruel, which
points to a lack of unified diagnostic criteria, methods
or resources among health sectors. These differences
are not so visible in children from 0 to 16 when they
are under pediatric supervision, in comparison with
older patients. This is probably due to the difficulty
of diagnosing CD in adults, as they might remain
asymptomatic or show non-classic forms of CD. Sero-
negative CD reaches up to 22% of all diagnosed cases
[7], which shows that this technique is insufficient to
be used in Primary Care as the only method to
discard CD. As a result, these patients can be
misdiagnosed with irritable bowel syndrome or other
gastrointestinal diseases [22]. The mean age at diag-
nosis at 32 years, highlights that CD is not only a
child’s disease, but one that can appear at any stage
of life [23, 24]. Diagnosis is more frequent during the
first and the fourth decade.
Differences among health sectors are important and it
is interesting to note that sectors 2, 4 and 8 have been
the most effective when detecting CD, both in 2011 and
2016, while sector 1 shows the lowest prevalence of all
in both studies (Table 8).
In Primary Care, we believe that there should be
ongoing training in this pathology and Specialist-Pri-
mary care coordination, in order to raise awareness of
Table 3 Demographic characteristics in patients with CD
(strong evidence group)
Characteristic 2016
Mean age (SD/Range) 38.97(20.85/2–102)
Female (%) 71.8
Mean age at diagnosis (SD/Range) 32.42 (21.05/0.5–98)
Mode (year of diagnosis) 2016
% cases/year (≤2010/2011/2012/
2013/2014/2015/2016)
37.5/8.3/8.7/10.3/11/11.5/12.6
Nationalities 36
Fig. 1 Age at diagnosis
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the process, to enhance suspicion not only with the
manifestation of classic and suggestive symptoms, but
also in the case of less obvious ones such as hyper-
transaminasemia, certain types of dermatitis or hyper-
coagulability [25].
Prevalence differences among sectors underlines the
need to establish diagnosis protocols, in order to raise
awareness and enhance specialists’ training, so that
they can give a clear and prompt diagnosis for CD
before prescribing a gluten free diet for life. These
measures lead not only to benefits for the patient, but
also to important savings for the health system [26–
28]. In this regard, it would be interesting to analyse
the 1198 cases in the weak evidence group that were
labelled under 729 additional descriptors related to
the disease. Furthermore, it would be interesting to
study their distribution according to health sector and
specialist, as well as to see whether these cases are fi-
nally confirmed as CD or not, and how long it takes
to reach a firm diagnosis.
Fasano [29] cites some of the causes that might be
behind the CD underdiagnosis: [1] the serological
markers are not always requested by general practi-
tioners and pediatricians; [2] the small intestine biop-
sies are not carried out routinely when performing
endoscopies; [3] problems when handling biopsy sam-
ples and [4] health insurance companies do not always
cover the costs of these tests. Following ESPGHAN rec-
ommendations [3], serological markers and intestine bi-
opsies should be included in an active and systematic
search in cases of gastrointestinal symptomatology or
other cases that are compatible with the disease, which
is not a general practice in Aragón. In the case of point
2, this would increase the workload for pathological
anatomy services and consumption in the endoscopy
units. Nevertheless, this would probably be compen-
sated by more and earlier diagnoses.
Quality of the information
The fact that CD does not have its own ICPC code and
the large number of associated descriptors used by gen-
eral practitioners to refer to CD makes it difficult to
reach a firm diagnosis and, therefore, any effective treat-
ment. For example, the use of discouraged terms [1]
such as gluten intolerance or gluten-sensitive enteropathy
may mislead the diagnosis as they can easily be taken for
a non-celiac gluten sensitivity instead of CD, especially
when different general practitioners may share access to
the same clinical record.
Fig. 2 Year of diagnosis
Table 4 Prevalence of CD by health sector with different
secondary health services
Health Sector Prevalence 2016
Sector 1 0.13%
Sector 2 0.44%
Sector 3 0.28%
Sector 4 1.16%
Sector 5 0.31%
Sector 6 0.26%
Sector 7 0.21%
Sector 8 0.34%
Table 5 Prevalence by age in Aragon and provinces
PREVALENCIA 0–14 15–29 30–44 45–59 60–74 75–89 ≥90
ARAGÓN 0.38% 0.47% 0.87% 0.34% 0.27% 0.18% 0.12%
Huesca 0.48% 0.79% 1.06% 1.04% 0.79% 0.40% 0.23%
Teruel 0.50% 0.33% 0.21% 0.21% 0.16% 0.08% 0.04%
Zaragoza 0.34% 0.41% 0.25% 0.20% 0.17% 0.13% 0.11%
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The lack of its own ICPC code and being coded
under code D99 “Disease digestive system, other” in
Primary Care lead family doctors to edit the descrip-
tor in order to identify the diagnosis, creating confu-
sion and unnecessary terminology variety. Therefore,
the fact that this label is editable hinders diagnosis
and epidemiological research. In 2011, this research
team identified 2041 patients with CD in 93 descrip-
tors using this same method. Hence, we can see that
we are facing a growing problem, as we found 293
labels in 2016 that refer to the same disease. Over
the last 25 years, this information tool has been
introduced in 12 out of the 17 Spanish autonomous
communities, as it is the best known and used infor-
mation system in Spain, with a market share of 60%
[30]. Consequently, we believe that these terminology
difficulties can be found in other Autonomous Health
Systems in Spain.
Fig. 3 Prevalence of celiac disease in Aragon, Spain. Prevalence lower than 1:700 is shown in grey. Image modified (own work), via Wikimedia
Commons, available at https://commons.wikimedia.org/wiki/File:Map_of_municipalities,_comarcas_and_provinces_of_Aragon.svg
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Additionally, the design of this information tool and
label edition by family doctors allow the use of
discouraged terms by the Oslo group to refer to CD
(such as gluten intolerance or enteropathy by gluten),
and its misuse prevents us from knowing how many
patients are actually suffering from this disease.
Although CD may fulfill World Health Organization
criteria for screening strategies in general population
[31], it seems that there is no sufficient consensus on
the relevance of promoting these programs [7, 13,
32–34]. While detection methods need to be im-
proved, we believe that active case search strategies
should be adopted. Thus, in line with the recommen-
dations of the British Society of Gastroenterology [7]
and the ESPGHAN [7], general practitioners should
prescribe serological study in patients with mild
gastrointestinal problems or with conditions associ-
ated to genetic risk, i.e., first-degree relatives, and an
endoscopy with biopsy when the disease is suspected,
e.g. malabsorption syndrome or a family history of
CD. In patients with positive serology or symptom-
atology who are referred to endoscopy, duodenal
biopsies are recommended. Finally, an HLA study for
first-degree family could be considered as a way of
discarding the disease, and thus avoiding future tests.
These strategies have proved to be cost effective [28,
32, 34, 35].
Further investigation is necessary to search for the
reasons behind prevalence differences, whether they
are due to access to health resources, to sociodemo-
graphic characteristics, to different diagnosis criteria
in the specialist teams or to differences in suspecting
and detecting in Primary Care and a correct remit-
tance to gastroenterological services.
In order to analyse this data, we must consider that,
although the access to the Health System in Spain is
free and universal, this data comes only from the Pri-
mary Care System and does not include those either
from private care systems or the community.
The absence of a single diagnosis descriptor that
covers CD means that we may be cautious when
interpreting its prevalence estimations. In 2011 the
implementation of electronic records in all Primary
Care Centres of Aragon was concluded. Although we
expected that a better knowledge of this tool would
lead to a greater use and greater unanimous criteria
when recording CD, 5 years later we can find that CD
labelling has increased by 315%. Giving CD its own
ICPC code will help to reduce the need to edit the
description field and, therefore, facilitate diagnosis
and research on this disease. We hope the protocol
for the diagnosis of CD recently developed in Spain
[36] helps to improve both case finding strategies and
the use of unified correct terms.
Finally, this increase of detected CD cases and other
chronic diseases in recent years, urges for a change in
Spanish primary care health system. We believe that
diagnosis and management of CD could be improved
by implementing a new clinical governance framework
in primary care [37]. All primary care systems should
be patient centered and issues such as quality assur-
ance, patient empowerment, patient and caregivers
engagement, EBHC courses and the improvement of
information and communication technologies will be of
great help to improve early diagnosis of CD and
adherence to the Gluten Free Diet in patients with CD
in Spain.
Table 6 Evolution of CD prevalence in Aragon 2011–2016
2011 2016
N patients with CD
in descriptors
2.042 in 93 descriptors 4534 in 293 descriptors
Prevalence Aragón 0.15% 0.35%
Huesca 0.36% 0.81%
Zaragoza 0.12% 0.25%
Teruel 0.07% 0.24%
Age mean (SD/Range) 34.82 (22.18/1–92) 38.97(20.85/2–102)
% Female 71.48% 71.8
Age at diagnosis
mean (SD/Range)
30.93 years,
(22.54/< 1–88)
32.42 (21.05/0,5–98)
Nationalities 21 36
Table 7 Comparison of standardized prevalences between 2011 and 2016
2011 2016
Crude Prevalence (%) Standardised Prevalence (%) (a) Crude Prevalence (%) Standardised Prevalence (%) (a) p value
Aragón 0.1512 0.1511 0.3464 0.3481 < 0.001**
Huesca 0.3585 0.3580 0.8120 0.8116 < 0.001**
Teruel 0.0668 0.0666 0.2383 0.2389 < 0.001**
Zaragoza 0.1154 0.1153 0.2535 0.2559 < 0.001**
(a) Standardised prevalence for age and gender
(**) Significant differences (p ≤ 0.05)
Note: we allow four decimal places to show differences
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Conclusion
The prevalence of CD in Aragón is far from the general
accepted figure of 1%. Additionally, the quality of the in-
formation available from Primary Care must be im-
proved due to the number of different terms general
practitioners use to refer to CD, as the use of many of
them is discouraged nowadays.
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